We examined the biological role of p12 in cisplatin-mediated responses by using murine ES p12 CDK2-AP1 knockout clones generated by a targeted disruption of murine p12 . Homozygous knockout clones showed an increased cellular proliferation along with an increase in S and a decrease in G2/M phase populations. Interestingly, ES p12 CDK2-AP1 knockout clones showed a resistance to cisplatin treatment along with an increased DNA repair activity assessed by host cell reactivation assay using a cisplatin-damaged reporter DNA and a significant reduction of apoptosis upon cisplatin treatment. By using stable p12 CDK2-AP1 short interfering RNA (siRNA) clones from human normal oral keratinocytes, we confirmed that downregulation of p12 CDK2-AP1 resulted in a resistance to cisplatin. More interestingly, cisplatin treatment resulted in a reduction of CDK2 kinase activity in control clones, but p12 CDK2-AP1 knockout clones showed a sustained CDK2 kinase activity. These data suggest that p12 CDK2-AP1 plays a role in cisplatin-mediated cellular responses by modulating CDK2 activity. These data further suggest p12 CDK2-AP1 is a potential gene therapeutic agent for oral/head and neck cancer in conjunction with DNA-damaging agents such as cisplatin.
We examined the biological role of p12 in cisplatin-mediated responses by using murine ES p12 CDK2-AP1 knockout clones generated by a targeted disruption of murine p12 . Homozygous knockout clones showed an increased cellular proliferation along with an increase in S and a decrease in G2/M phase populations. Interestingly, ES p12 CDK2-AP1 knockout clones showed a resistance to cisplatin treatment along with an increased DNA repair activity assessed by host cell reactivation assay using a cisplatin-damaged reporter DNA and a significant reduction of apoptosis upon cisplatin treatment. By using stable p12 CDK2-AP1 short interfering RNA (siRNA) clones from human normal oral keratinocytes, we confirmed that downregulation of p12 CDK2-AP1 resulted in a resistance to cisplatin. More interestingly, cisplatin treatment resulted in a reduction of CDK2 kinase activity in control clones, but p12 knockout clones showed a sustained CDK2 kinase activity. These data suggest that p12 CDK2-AP1 plays a role in cisplatin-mediated cellular responses by modulating CDK2 activity. These data further suggest p12 CDK2-AP1 is a potential gene therapeutic agent for oral/head and neck cancer in conjunction with DNA-damaging agents such as cisplatin.
Introduction
Clinic chemotherapy using DNA-damaging agents such as cisplatin continues to be a well-accepted cancer treatment (Khuri et al., 2000; Andreadis et al., 2003; Milas et al., 2003; Boulikas and Vougiouka, 2004) . Cisplatin is widely used for treating a variety of malignancies including testis, lung, ovary, esophagus, bladder carcinoma, adrenal cortex, breast, and head and neck, but it is known that cisplatin alone has a palliative effect only, and for a curative intent should be used in combination with radiation or other drugs such as 5-fluorouracil (Khuri et al., 2000; Milas et al., 2003) . There are several limitations associated with the use of cisplatin (Kim and Glisson, 2003; Milas et al., 2003) . There are serious side effects, notably renal toxicity, emesis, neurotoxicity, bone marrow suppression, and hearing loss (Tsutsumi et al., 1991; Fossa et al., 1995) . Another major impediment to the clinical success of cisplatin is cellular resistance to the drug, through either intrinsic or acquired resistance . The immunity of cells to cisplatin cytotoxicity has been attributed to several processes including an increase in the repair of cisplatin-DNA adducts (Perez, 1998; Runger et al., 2000; Mukai et al., 2002) . It has been reported that dysregulation of certain genes that are involved in DNA repair could lead to the increase in DNA repair and result in cisplatin resistance. These include DNA polymerase b, ERCC1, proliferating cell nuclear antigen (PCNA), c-Fos and cMyc, and p53 (Ferry et al., 2000; Li et al., 2000; Bergoglio et al., 2001; Higuchi et al., 2003) . Disruption of the gene encoding for p53 in head and neck squamous cell carcinoma cells increased their sensitivity to cisplatin (Bradford et al., 2003) .
Elucidation of cellular mechanisms governing the action of chemotherapeutic agents has been the subject of studies to understand acquired cellular resistance to chemotherapeutic treatment. Detailed knowledge on the mechanisms of cellular resistance will lead to the design of new drugs and improve the overall response rates and long-term survival obtained for a broader range of tumors. It has been shown that treatment of cells with DNA-damaging cisplatin invokes a series of cellular responses, including damage recognition pathways, alteration of cell cycle regulation, growth arrest and apoptosis, and induction of DNA repair machinery (Fink et al., 1998; Harrington et al., 1998; Kolodner and Marsischky, 1999; Agami and Bernards, 2000; Knudsen et al., 2000; Lan et al., 2002) . It is known that cisplatin induces mismatch repair-dependent cyclin D1 loss, reduction in CDK2 activity, and activation of RB, resulting in G1 arrest. It is also known that cisplatin invokes the G2/M block (Harrington et al., 1998; Knudsen et al., 2000; Lan et al., 2002) . Studies have shown that cisplatin treatment can activate several cell signaling pathways including the mitogen-activated protein (MAP) kinase, stress activated protein (SAP) kinase, and protein kinase C (Rubin et al., 1992; Derijard et al., 1994; Kharbanda et al., 1995; Gately et al., 1996; Zanke et al., 1996; Hoffmann et al., 2002; Song et al., 2004) . Cisplatin treatment is known to result in cell-type and dose-dependent cellular responses. A low dose of cisplatin treatment resulted in an immediate induction of p53-dependent DNA repair, but a higher dose of cisplatin-induced p53-dependent apoptosis (Offer et al., 2002) . Like other cellular responses to extracellular stimuli, cisplatin-induced responses are under the control of a complex network of signaling pathways whose exact mechanisms remain unclear. p12
, formerly known as deleted in oral cancer-1 (DOC-1), is a 115-aa nuclear polypeptide that is downregulated in B70% of oral cancers . p12 CDK2-AP1 is a highly conserved, ubiquitously expressed gene located on chromosome 12q24 and has a closely related gene, DOC-1R, located on chromosome 11q13 (Tsuji et al., 1998; Zhang et al., 1999) . In the hamster buccal pouch carcinogenesis model, the p12 CDK2-AP1 gene undergoes a loss of heterozygosity that leads to a marked reduction of messenger RNA and protein expression. Ectopic expression of p12 CDK2-AP1 in hamster oral cancer cells results in the reversion of several malignant phenotypes, including morphology, anchorage-independent growth, and doubling time (Todd et al., 1995) . During human oral cancer development, p12
CDK2-AP1 gene and protein expression are also markedly reduced . Recently, p12 CDK2-AP1 has been shown to be a S phase regulator through two important cellular partners: CDK2 and DNA polymerase-a/primase Shintani et al., 2000) . Like other cell cycle regulators, p12
CDK2-AP1 has also been implicated in apoptosis both in vitro and in vivo, although the mechanisms are less well defined (Cwikla et al., 2000; Kohno et al., 2002) . We have also found that p12 CDK2-AP1 mediates TGF-binduced growth inhibition (Hu et al., 2004) . A recent report shows that p12 CDK2-AP1 expression levels are differentially downregulated in microsatellite-unstable colorectal cancer cell lines compared to microsatellitestable cell lines (Yuan et al., 2003) . It is hypothesized that downregulation of p12 CDK2-AP1 expression is associated with microsatellite-instability and reduction in apoptotic index.
In this report, we investigated a functional role for p12 CDK2-AP1 whose expression is upregulated by cisplatin treatment. By using murine ES p12 CDK2-AP1 knockout clones, we demonstrated that deficient expression of p12 CDK2-AP1 resulted in a cellular resistance to cisplatin treatment with an increased repair activity against cisplatin-damaged DNA and a reduced apoptosis upon cisplatin treatment. We also showed that gene silencing of p12 CDK2-AP1 in human normal oral keratinocytes led to resistance to cisplatin treatment. Furthermore, ES p12 CDK2-AP1 knockout clones showed altered CDK2 kinase activity compared to control lines. These data support that p12 CDK2-AP1 plays a role in cisplatinmediated cellular growth inhibition and apoptosis and possibly functions against DNA repair mechanisms. Our data suggest that modulation of CDK2 activity might be a role of p12 CDK2-AP1 in this process. Conversely, these data also suggest that p12 CDK2-AP1 can serve as a potential gene therapeutic tool in combination with future chemotherapeutic interventions of head and neck/oral cancers.
Results

Cisplatin induces p12
CDK2-AP1 mRNA and protein p12 CDK2-AP1 is a cell cycle regulator and growth suppressor that negatively regulates CDK2 . Furthermore, its involvement in cellular apoptosis has been implicated (Cwikla et al., 2000; Kohno et al., 2002; Yuan et al., 2003) . In order to investigate how p12 CDK2-AP1 plays a role in the apoptotic pathway, we examined the effects of the genotoxic reagent cisplatin on p12 CDK2-AP1 expression. Figure 1a shows that treatment of HeLa cells with cisplatin-induced p12 CDK2-AP1 protein ( Figure 1a ) and upregulated p12 CDK2-AP1 mRNA as assessed by semiquantitative RT-PCR (Figure 1b) . We have also observed the induction of p12 CDK2-AP1 expression by cisplatin in immortalized normal human oral keratinocytes (OKF6tert1), primary oral keratinocytes established from the C57/B6 mouse, and in the SCC15 human malignant oral squamous cell carcinoma line by Western analysis (data not shown). We have cloned the human p12 CDK2-AP1 promoter sequence and generated luciferase reporter constructs. Reporter assays on human p12 promoter in HeLa cells after cisplatin treatment resulted in induction of promoter activity, strongest in the À670 construct (Figure 1c ), which suggests that induction of p12 CDK2-AP1 by cisplatin might be a transcriptional event and the human p12 promoter harbors cisplatin responsive cis-regulatory element(s). We have also observed that cotransfection of p53 with the p12 CDK2-AP1 reporter construct did not induce promoter activity of p12 , implying that this event is not a p53-dependent process (data not shown).
Generation of Murine ES p12
CDK2-AP1 knockout clones
To elucidate the physiological function of p12 CDK2-AP1 , we generated cell lines with p12 CDK2-AP1 gene disrupted. The mouse genomic p12 CDK-AP1 sequence was obtained by BLAST search of the mouse chromosome using mRNA sequence AK004852. To construct the targeting vector for p12
, we designed PCR primers that amplify the genomic fragments from the end of intron 1 and the beginning of intron 3. Homologous recombination would result in the replacement of exons 2 and 3 with the cytosine deaminase and neomycin-resistance genes ( Figure 2a ). The 5 0 arm and 3 0 arm genomic fragments were PCR amplified from murine embryonic stem cell (ES-LW1) genomic DNA by using specific primer sets as described in Materials and methods. The resulting 1.7 kb upstream and 1.5 kb downstream fragments were inserted into the pTKLNCL targeting vector (from Dr Rick Mortensen, University of Michigan) (Mortensen et al., 1992) . After electroporation, heterozygous clones were selected in ES medium containing G418 (0.4 mg/ml). Among 288 clones that were subjected to PCR and Southern analysis, we have identified three heterozygous clones (clones 63, 272, and 284) ( Figure 2b ). To establish homozygous knockout clones, we have further selected out by spontaneous mitotic crossing over with a high concentration of G418 (2 mg/ ml). The resulting clones were analysed by PCR and southern analyses. Figure 2c shows part of the analysis that we have used to confirm the homozygous knockout of p12 CDK2-AP1 in selected ES cells. For this multiplex PCR analysis, we designed two specific primer sets. One was targeted for the endogenous genomic intron 2 sequence of p12 CDK2-AP1 and the other was for the exogenous cytosine deaminase that would be integrated into the genome by homologous recombination. After multiplex PCR amplification, the wild type (WT) clones showed the presence of the intron 2 sequence in the genome (239 bp), while the heterozygous knockout clones (clone 272 and 284) showed the presence of both intron 2 and the 460 bp exogenous cytosine deaminase gene fragment. The homozygous knockout clones showed the loss of the intron 2 sequence and the presence of the exogenous cytosine deaminase gene fragment by homologous recombination in both alleles. CDK2-AP1 mRNA after cisplatin treatment was also analysed by RT-PCR. HeLa cells were treated with 20 mM cisplatin for 3 h and total RNA was prepared. The result of RT-PCR with a specific primer set for human p12 showed a significant induction at the level of mRNA after cisplatin treatment. GAPDH was used for normalization control. (c) Human p12 CDK2-AP1 promoter reporter constructs were transiently transfected into HeLa cells and the luciferase reporter activity was monitored after treatment with cisplatin. The result showed an activation of the p12 CDK2-AP1 promoter by cisplatin treatment, implying that p12 CDK2-AP1 contains cis-element(s) that responds to cisplatin-induced signaling and also suggesting that the induction of p12 CDK2-AP1 by cisplatin is transcriptionally controlled The effect of targeted gene disruption of p12 CDK2-AP1 was confirmed by examining the expression of p12 . For RT-PCR analysis, total RNA was isolated from ES clones and a gene fragment of p12 CDK2-AP1 was amplified by using a specific primer set for murine p12 CDK2-AP1 (against the end of exon 1 and the beginning of exon 4). The integrity of RNA was assessed by RT-PCR with GAPDH primer (data not shown). As shown in Figure 3a , WT clone showed the amplification of the expected fragment (443 bp). Heterozygous knockout clones (272 and 284) showed expression of intact p12 CDK2-AP1 mRNA (443 bp) and also a smaller fragment (250 bp), while all homozygous knockout clones (272-9, 272-10, 272-3, and 284-7) showed disrupted expression of p12 CDK2-AP1 mRNA (exclusively the 250 bp fragment). After homologous recombination, the targeting construct is integrated between introns 1 and 3. This results in intact exons 1 and 4, but disrupted exons 2 and 3 (replacement with the targeting construct). RT-PCR with a primer set against exons 1 and 4 would then result in the amplification of a heterologous transcript that is read through from the p12 CDK2-AP1 promoter. We also examined the level of p12 CDK2-AP1 mRNA by Northern analysis (Figure 3b ). Equal amount of total RNA from ES clones was separated on a 1% formaldehyde gel and the blotted RNA was probed with murine p12 CDK2-AP1 cDNA probe (Kim et al, 2001 ). Compared to WT and heterozygous knockout clones that showed the presence of intact murine p12 CDK2-AP1 mRNA size, the homozygous knockout clones showed loss of p12 CDK2-AP1 mRNA and the appearance of a disrupted fragment that may contain a heterologus transcript from homologous recombination (Figure 3b ), as observed in RT-PCR analysis shown in Figure 3a . The subsequent effect of disrupted p12 CDK2-AP1 on final protein production was examined by Western analysis. Figure 3c shows the expression of p12 CDK2-AP1 protein in WT and heterozygous clones (272, 284, and 63), while p12
protein expression was completely abolished in homozygous clones (272-9, 272-10, 272-13, and 284-7).
Increased cellular proliferation and altered cell cycle profile in p12 CDK2-AP1 deficient ES cells p12 CDK2-AP1 is known to be inhibitory to cellular growth, and ectopic expression of p12 CDK2-AP1 has been shown to change the cell cycle profile with a decrease in S phase and an increase in G1 phase . In order to examine the cellular effect of knockout of p12 CDK2-AP1 on growth of murine ES cells, we measured the cellular proliferation of three ES p12 CDK2-AP1À/À clones (272-10, 272-13, and 284-7) and compared it to the parental ES-LW1 (WT) and two heterozygous ES p12 CDK2-AP1 þ /À clones (Het 272 and Het 284). For analysis, equal numbers of cells were seeded on a 96-well plate and proliferation was measured by using the CCK-8 cell counting kit (Alexis Biochemical Corp, San Diego, CA, USA). The growth profile was presented as a ratio against the day 1 measurement (after 24 h incubation). As shown in Figure 4a , the p12 CDK2-AP1À/À clones showed increased cellular proliferation compared to both WT and p12
clones (up to two fold, Po0.05). Interestingly, there was a reciprocal relationship between the level of p12 and the proliferation of ES cells, in that the growth rate of the homozygous knockout clones with null expression was higher than the heterozygous knockout clones that showed intermediate levels of p12 CDK2-AP1 and the WT cells with intact levels of p12 CDK2-AP1 showed the lowest rate of growth. We also examined the cell cycle profiles of ES clones by DNA FACS analysis (Figure 4b ). Compared to WT cells, there was no significant change in G1 population (2-3% alteration), but there was a significant increase in S phase (up to 13.3%, Po0.0001) and decrease in G2/M phase (up to 90%, Po0.0003).
Murine ES p12
CDK2-AP1À/À cells showed resistance to cisplatin with an increased DNA repair activity and significantly reduced apoptosis , we hypothesized that p12
CDK2-AP1 mediates -deficient cell lines (clones 272-10, 272-13, and 284-7) showed enhanced cellular growth upon cisplatin treatment (20 mM). Significant resistant effect against cisplatin was observed after 4 days (Po0.033) of treatment. From this data, we concluded that knockout of p12 CDK2-AP1 in murine ES cells altered cellular responses to cisplatin and conferred resistance. This further suggests that p12 CDK2-AP1 mediates cisplatin-induced cellular growth arrest or apoptosis. Also, this leads to the hypothesis that knockout of p12 CDK2-AP1 may alter cellular responses and result in enhanced DNA repair and resistance to cisplatin treatment in ES knockout clones. In order to investigate the consequence of knockout of p12 in cisplatin-induced DNA damage repair, we performed the host cell reactivation assay. After transiently cotransfecting murine ES clones with cisplatin-damaged pGL3-Luc reporter plasmid (firefly luciferase) along with pRL-CMV reporter (Renilla luciferase), the DNA repair activity was determined by calculating the relative activity of these luciferases and presented as a foldincrease over WT cells. As shown in Figure 6a , the 272-10 p12 CDK2-AP1À/À clone showed higher DNA repair activity on cisplatin-damaged DNA compared to WT cells. It was also noted that heterozygous knockout clone (Het 272) showed an intermediate level of DNA repair activity. In addition to an induction of DNA repair mechanism, cisplatin is also known to induce apoptosis in cultured cells (Perez, 1998; Knudsen et al., 2000; Lan et al., 2002) . Based on our previous findings suggesting p12 CDK2-AP1 as a mediator in apoptosis, we examined if deletion of p12 CDK2-AP1 altered apoptotic potential in murine ES cells (Cwikla et al., 2000; Kohno et al., 2002) . We determined the level of apoptosis before and after cisplatin treatment by using CDK2-AP1À/À cells showed resistance to cisplatin treatment. Murine ES clones were seeded on a 96-well plate and treated with 20 mM of cisplatin for 5 days. The number of viable cells was measured by using the cell counting kit (CCK-8, Alexis Biochemical). The reading was normalized against day 1 (after overnight incubation without treatment) as a starting point and the fold-increase was calculated by dividing the average number of treated cells by the average number from untreated cells. Significant resistant effect against cisplatin was observed after 4 day (Po0.033) of treatment. The data was analysed by using paired Student's t-test p12 CDK2-AP1 knockout induces resistance to cisplatin Y Kim et al ApoAlert Annexin V-EFGP kit (BD Biosciences-Clontech, Palo Alto, CA, USA). As shown in Figure 6b , ES p12 CDK2-AP1 þ /À (Het 272) and ES p12 CDK2-AP1À/À clones (272-9 and 272-10) showed a significantly reduced level of apoptosis compared to WT (P ¼ 0.0006, P ¼ 4.6À10
À5
, and P ¼ 7.76 Â 10 À5 respectively). Again, we found that heterozygous knockout clone showed an intermediate level between WT and homozygous knockout clones. Taken together, these data suggest that knockout of p12 CDK2-AP1 in murine ES cells may confer resistance to cisplatin treatment by inducing cellular DNA damage repair activity and reducing an apoptotic potential in murine ES cells. This also implies that p12 CDK2-AP1 plays a role in cisplatin-induced cellular responses by mediating pathway(s) against DNA repair mechanism and promoting cellular apoptosis.
Stable p12
CDK2-AP1 short interference RNA (siRNA) cell lines from human normal oral keratinocytes also showed a resistance to cisplatin treatment ) (Elbashir et al., 2001; Donze and Picard, 2002; Leirdal and Sioud, 2002) . We have designed and tested several different siRNA sequences by using plasmid-based siRNA constructs (pSilencer 3.1-hygro from Ambion, Austin, TX, USA) and used the most effective sequence to stably transfect OKF6tert1 cells. The clones were selected by culturing in medium containing 50 mg/ml hygromycin and examined for p12 CDK2-AP1 expression by Western analysis. As shown in Figure 7a , stable p12 CDK2-AP1 siRNA clones showed much reduced expression levels of p12 CDK2-AP1 (up to a 70% reduction compared to pSilencer 3.1-hygro vector (V) and pSilencer 3.1-negative control clones (N)). We have also determined cellular growth of p12 CDK2-AP1 siRNA clones by cellular proliferation assay and found that downregulation of p12 CDK2-AP1 resulted in enhanced overall growth of oral keratinocytes (data not shown). We tested if gene silencing of p12 CDK2-AP1 has any effect on cisplatin treatment on oral keratinocytes by measuring viable cell numbers after treatment. A shown in Figure 7b , we observed that downregulation of p12 CDK2-AP1 resulted in resistance to cisplatin treatment, more viable cells in p12 CDK2-AP1 siRNA clones (C1 and C9) compared to control clones (vector (V) and negative siRNA (N) clones) 4 days after treatment with various concentrations of cisplatin. This result is consistent with the murine ES knockout clone experiments and strongly supports the conclusion that p12 CDK2-AP1 mediates cisplatin-induced growth arrest and/or cell death, and downreguation of p12 CDK2-AP1 expression resulted in alteration in cisplatin responses through p12 . Abrogated CDK2 activity in cisplatin-treated ES p12 CDK2-AP1 knockout clones
It has been shown that cisplatin treatment on cultured cells evoked an attenuation of cyclin D1 and in turn resulted in a reduction of CDK2 activity (Lan et al., 2002) . Furthermore, p12 CDK2-AP1 is known to function as a growth suppressor by negatively regulating CDK2 activity and further exerts its effect on RB phosphorylation (Shintani et al., 2000; Hu et al., 2004) . In order to clone 272-10) with cisplatin-damaged pGL3-Luc reporter plasmid (firefly luciferase) along with pRL-CMV reporter (Renilla luciferase). The DNA repair activity was determined by calculating relative activity of these luciferases and presented as a fold-increase over WT cells. 272-10 p12 CDK2-AP1À/À clone showed significantly higher DNA repair activity (Po0.0008) on cisplatin-damaged DNA compared to WT cells. The data was analysed by using paired Student's t-test. (b) Knockout of p12 CDK2-AP1 in murine ES cells resulted in a reduced cellular apoptosis upon cisplatin treatment. The level of cellular apoptosis was measured in ES clones (WT, p12 CDK2-AP1 þ /À clone 272, and p12 CDK2-AP1À/À clone 272-10 and 272-13). After treating with 25 mM cisplatin for 24 h, apoptosis was measured by using ApoAlert Annexin V-EGFP kit (BD Biosciences Clontech, Palo Alto, CA, USA). Unstained WT cells were used for a negative control and for positive control, WT cells were treated with 2 mM actinomycin D (Sigma, St Louis, MO, USA) for 4 h before analysis. Samples were analysed by using FACS Scan (BD Biosciences, San Jose, CA, USA) and data were analysed by using Cell Quest software (BD Biosciences, San Jose, CA, USA). Samples were in quadruplicate and P-value was determined by paired Student's t-test against WT (*P ¼ 0.0006, **P ¼ 4.6 Â 10
À5
, and ***P ¼ 7.76 Â 10 is related to cisplatin resistance conferred by deletion of p12 CDK2-AP1 in murine ES cells, we performed in vitro CDK2 kinase activity assay after treating cells with 25 mM cisplatin or 16 h. As shown in Figure 8 , we found that deletion of p12 CDK2-AP1 (clones 272-9 and 272-10) resulted in an induced CDK2 kinase activity against Rb-C fragment compared to WT and heterozygous knockout clone (clone 272). More interestingly, the differential was more prominent after cisplatin treatment. The activity was normalized against either the level of CDK2 protein or the amount of Rb-C fragment and the result was not significantly different. In accordance with the previous published result by Lan et al., cisplatin treatment resulted in a reduction of CDK2 kinase activity in control cell lines (WT and 272). However, the homozygous knockout clones (272-9 and 272-10) showed a sustained CDK2 kinase activity. These data confirm that p12 CDK2-AP1 is a negative regulator of CDK2. It also suggests that a loss of p12 CDK2-AP1 result in a sustained CDK2 activity even after cisplatin treatment, which may block a cisplatin-induced cellular pathway. This would in turn result in an inhibition of growth arrest and apoptosis by cisplatin, and eventually lead to a cellular resistance to cisplatin.
Discussion
Chemotherapy using DNA-damaging agents, such as cisplatin, has been widely used for the treatment of advanced carcinomas (Loehrer and Einhorn, 1984; Ozols and Williams, 1989; Ozols, 1992) . Regardless of its effectiveness, severe side effects and acquisition of resistance due to repeated administrations has been a limiting factor in clinical use. In addition to the improvement of efficacy and amelioration of side effects, understanding and establishing cellular mechanisms governing the cytotoxicity of cisplatin and development of resistance should aid the design of new drug and invention of new therapeutic strategies.
Multiple potential cellular and molecular mechanisms of resistance to cisplatin have been identified in cisplatin-resistant cell lines (Perez, 1998) . These include decreased cisplatin accumulation, increased cellular thiol levels, increased repair of platinum-DNA damage, and enhanced capacity to tolerate cisplatin-induced damage. Decreased cisplatin accumulation has been siRNA clones (C1 and C9) was compared to controls (vector (V) and negative siRNA (N) clones). The result showed cellular resistance to cisplatin after treatment with various concentration of cisplatin for 4 days Figure 8 Sustained CDK2 activity in ES p12 CDK2-AP1 knockout clones after cisplatin treatment. In vitro CDK2 kinase activity was compared between wild-type ES cells (WT), p12 CDK2-AP1 þ /À (272) and p12
CDK2-AP1À/À (272-9 and 272-10) as described in Materials and methods. (a) Cells were treated without or with 25 mM cisplatin for 16 h and the CDK2 activity was measured from immunoprecipitated CDK2 by using Rb-C fragment as a substrate. The level of CDK2 protein was examined by Western analysis. (b) In vitro CDK2 kinase activity was depicted as a graph after normalizing against the level of CDK2 protein p12 CDK2-AP1 knockout induces resistance to cisplatin Y Kim et al observed in most cisplatin-resistance models Perez et al., 1990) . However, such changes do not generally correlate with the magnitude of resistance observed. Thus, it is likely that additional mechanisms contribute to cellular resistance to cisplatin. Cellular inactivation of potent cisplatin is another mechanism preventing cisplatin from reacting with intracellular target molecules. Intracellular glutathione (GSH) covalently binds cisplatin and can inhibit conversion of platinum-DNA monoadducts to potentially cytotoxic crosslinks (Dedon and Borch, 1987; Mistry et al., 1993) . It has been reported that linear correlations between GSH levels and cisplatin resistance exist in human renal, bladder, and ovarian cancer cell lines and in human ovarian tumors (Ahn et al., 1994; Pendyala et al., 1997) . Removal of cisplatin from its target can minimize cisplatin-induced damage. Some cisplatin-resistant cell lines have an increased capacity to repair cisplatin-DNA damage and cisplatin cytotoxicity Masuda et al., 1988; Parker et al., 1991; Johnson et al., 1994) . Tolerance to damage is another common and potentially important determinant of cisplatin sensitivity (Johnson et al., 1997) . It is not known how tolerance to DNA damage is conferred. The capacity of resistant cells to synthesize DNA past adducts can induce tolerance. Alternatively, DNA damage in resistant cells may no longer trigger a signal to undergo apoptosis. It has been increasingly studied how altered sensitivity contributes to cisplatin resistance as genes involved in apoptosis are defined.
The specific mechanism(s) that trigger apoptosis in response to cisplatin have not been clearly established, even though there are considerable evidences supporting that cisplatin induces cellular apoptosis (Offer et al., 2002) . Mismatch repair (MMR) proteins and highmobility group (HMG) proteins are types of proteins recognizing cisplatin-induced DNA damage (Karran and Bignami, 1994; Fishel and Kolodner, 1995) . Loss of MMR was accompanied by loss of p53 function, which could disrupt cell cycle and apoptosis regulation and contribute to further genomic instability (Aebi et al., 1996; Anthoney et al., 1996) . The HMG proteins recognize some structural distortions of DNA, and their interactions with distorted DNA regulate transcription. HMG protein binding to cisplatin-DNA adducts could trigger apoptosis and modulate cell cycle events subsequent to DNA damage. p53 is a known critical regulator of apoptosis and cisplatin induced stabilization and nuclear translocation of p53 (Kastan et al., 1991; Fritsche et al., 1993) . There are evidences that inactivation of the p53 DNA-binding domain can confer resistance to cisplatin. p53 also directly affects expression of downstream genes that regulate sensitivity to apoptosis, activating transcription of Bax (promoting apoptosis) and repressing transcription of Bcl-2 (inhibiting apoptosis) (Miyashita et al., 1994; Miyashita and Reed, 1995) . Altered expression of these downstream effectors involved in apoptosis can affect cisplatin sensitivity.
Among several cellular responses elicited by cisplatin, alteration of cell cycle regulation has been one of the prominent and early events that lead to the downstream phenotypic changes. In this regard, investigation on cell cycle regulatory elements that are affected by cisplatin could lead to the identification of primary target(s) that can be manipulated to amend any dysregulated cellular mechanisms resulting in hyposensitivity and resistance to cisplatin administration. Previous studies showed that cisplatin treatment leads to G1 arrest through the attenuation of cyclin D1 and activation of RB by dephosphorylation via inhibition of CDK2 activity (Lan et al., 2002) . It has also been shown that cisplatin can induce G2/M arrest of treated cells (Walker et al., 1995) . It is known that CDK2 can work at the G1/S phase through interaction with cyclin E and also S and G2/ M phase through interaction with cyclin A. Overexpression of CDK2 has been shown to induce premature escape from G2/M phase arrest by cisplatin in human fibroblasts (Walker et al., 1995) . It is also known that G1 arrest by cisplatin treatment can be achieved by a slower p53-dependent process (Agami and Bernards, 2000) . In this study, we have observed a cisplatininduced expression of p12 CDK2-AP1 that has previously been shown to interact with CDK2 and functions as an inhibitor, resulting in dephosphorylation of RB Hu et al., 2004) . In order to investigate the biological role and significance of p12 CDK2-AP1 in cisplatin-mediated cellular responses, we utilized murine ES p12 CDK2-AP1 knockout cells. The data showed that nulligenic expression of p12 CDK2-AP1 resulted in cellular resistance to cisplatin cytotoxicity, implying that p12 CDK2-AP1 plays a role as a mediator in cisplatinmediated pathways, rather than cellular epigenetic responses for survival. This finding has been confirmed in human normal oral keratinocytes by generating stable p12 CDK2-AP1 siRNA clones. Gene silencing of p12 CDK2-AP1 also resulted in cellular resistance to cisplatin treatment. Interestingly, we also have observed that knockout of p12 CDK2-AP1 resulted in enhanced DNA repair activity against cisplatin-damaged DNA as assessed by host cell reactivation assay and also reduced apoptotic index. From these data, we demonstrated that cellular resistance to cisplatin in murine ES p12 CDK2-AP1 is due to the induced DNA repair activity and reduced apoptosis upon cisplatin treatment. There may be an intricate cellular balance between DNA damage repair and apoptosis upon external damages. p12 CDK2-AP1 itself may function as an indirect negative regulator of cell proliferation by mediating growth arrest and inducing apoptosis upon genotoxic damages rather than repair, subsequently protecting cells from genomic alterations. This may be related to the reduced apoptotic versus mitotic index reported in the hamster oral cancer model which also showed downregulation of p12 CDK2-AP1 (Kohno et al., 2002) . Also, the differential downregulation of p12 CDK2-AP1 has been associated with microsatellite instability and reduced apoptotic index in colorectal cancer cell lines (Yuan et al., 2003) . However, the mechanism is not clear on how the knockout of p12 CDK2-AP1 resulted in enhanced DNA repair activity and reduced apoptosis. It is speculated that altered cell cycle regulation by knocking out p12 CDK2-AP1 expression knockout clones and a sustained CDK2 kinase activity in knockout clones even after cisplatin treatment. Combined with other reported studies, we speculate that induction of p12 CDK2-AP1 by cisplatin inhibits CDK2 that in turn activates RB by hypophosphorylation, leading to G1 arrest. More detailed cell cycle studies will confirm this model. Also, in order to confirm increased CDK2 kinase activity upon deletion of p12 CDK2-AP1 , we are investigating the effect of restoration of WT p12 and CDK2 binding mutant form of p12 CDK2-AP1 in murine ES p12 CDK2-AP1 knockout cells. Overall, the data presented in this study supports the hypothesis that p12 mediates cisplatin-induced cellular responses, presumably through its effect on cell cycle regulation involving CDK2 and RB that may be negatively regulating the DNA repair process and promoting cellular apoptosis. Also, this study suggests that p12
CDK2-AP1 should have clinical value in potentiating the actions of cisplatin. This will help alleviate associated side effects by improving drug efficacy and also prevent acquired resistance.
Materials and methods
Materials
Cell culture media (DMEM and KSFM) and cell culture supplies including antibiotics were purchased from Invitrogen (Carlsbad, CA, USA). Fetal bovine serum was obtained from HyClone (Logan, UT, USA). The Lipofectamine 2000 reagent was from Invitrogen (Carlsbad, CA, USA) and FuGene6 was from Roche Diagnostics (Indianapolis, IN, USA). All restriction enzymes used were purchased from New England Biolabs (NEB, Beverly, MA, USA). The secondary anti-rabbit IgG-HRP and ECL reagent were purchased from Amersham (Piscataway, NJ, USA). Reagents used for RT-PCR were from Bio-Rad (Bio-Rad, Hercules, CA, USA) and PerkinElmer (Boston, MA, USA). The CCK-8 kit was purchased from Alexis Biochemicals and propidium iodide was purchased from Sigma-Aldrich. RNaseA was obtained from Calbiochem (San Diego, CA, USA). Cisplatin (cis-diamminedichloroplatinum II) and all other chemical reagents were purchased from Sigma-Aldrich (St Louis, MO, USA).
Construction of the p12 CDK2-AP1 targeting vector
The mouse genomic p12 CDK2-AP1 sequence was located by BLAST search of the mouse chromosome using mRNA sequence AK004852. To construct the targeting vector of p12 , the downstream genomic DNA fragment was generated by PCR using mouse strain 129 ES-LW1 genomic DNA with primers (3 0 U5(5 0 CATGGGTTTCTGAGAAGGG AATGATAG3 0 ) and 3 0 D5 (5 0 CATCGTCAGTTACTGCAA AATGTCCTC3 0 )). The resulting 2.5 kb fragment was inserted into the pCR2.1-TOPO vector from Invitrogen. After validation by DNA sequencing, a 1.5 kb BamHI fragment was inserted into the pTKLNCL targeting vector obtained from Dr Rick Mortensen (University of Michigan). The upstream genomic DNA fragment corresponding to p12
CDK-AP1 was also generated by PCR using primers (5 0 U4 (5 0 GTCGACATTGG GAAATATGGCCTCAAACAAGTAG3 0 ) and 5 0 D4 (5 0 GTC GACAAAAGGTCCTCACTGTTACACACACAC3 0 )). A 1.7 kb fragment was inserted into the pCR2.1-TOPO vector from Invitrogen. The final sequence was confirmed using dye terminator sequencing beginning with M13 forward and M13 reverse ends. The 1.7 kb SalI fragment was inserted into the pTKLNCL-P12 targeting vector. This construct targeted the deletion of exons 2 and 3 of the murine p12 .
Generation of p12
CDK2-AP1 deficient ES Cells
The targeting vector was linearized using XhoI. Electroporation into ES-LW1 cells was performed by the UCLA ES core facility. In total, 288 single clones were grown in the presence of G418 at 0.4 mg/ml. DNA was isolated and homologous recombinants were identified by Southern blotting using a 3 0 probe (600 bp BamH I/BstXI fragment outside of pTKLNCL-P12) and a 5 0 probe (PCR product using primers U1 (5 0 GCCC CAACAGATGCCAAGTAGTG3 0 ) and D1 (5 0 TGGAATCA ACATTTGGACACAAGACC3 0 ), which generated a 151 bp fragment outside of pTKLNCL-P12)). Heterozygous cells were expanded for several passages and plated onto five gelatincoated 100 mm dishes at a density of 5 Â 10 5 cells/dish. After 24 h, G418 was added to the final concentration of 2 mg/ml and the cells were grown until visible colonies formed. Clones were characterized using a multiplex PCR strategy. Primer set 1 (CDU2 (5 0 GCCTTCTTGACGAGTTCTTCTGAG3 0 ) and CDD2 (5 0 TGGATGTGGAATGTGTGCGAG3 0 )) generates a 460 bp fragment within the cytosine deaminase gene located within pTKLNCL-P12). Primer set 2 (I2U (5 0 ATGGGGATG GATGTGTGAGAGG3 0 ) and I2D (5 0 TGGGTTCAAGGAA GTGGACTAATG3 0 )) generates a 239 bp fragment from intron 2, which is absent in a successful homologous recombination).
CDK2-AP1 siRNA clones from human normal oral keratinocytes Several human p12 CDK2-AP1 siRNA target sequences were designed and cloned into the pSilencer 3.1-H1 hygro vector (Ambion, Austin, TX, USA). Clones were selected and verified by DNA sequencing. Plasmid DNA for transfection was prepared by using Qiagen Endofree Maxi kit (Qiagen, Valencia, CA, USA) and test transfection was carried out with HeLa cells. The results were analysed by RT-PCR, Northern, and Western analyses and the best siRNA target site for the p12 CDK2-AP1 gene was selected for generating stable siRNA cell lines in immortalized human normal oral keratinocytes (OKF6tert1) (Dickson et al., 2000) . The cells were grown in KSFM medium supplemented with 25 mg/ml bovine pituitary extract, 0.4 mM CaCl 2 , 1 ng/ml EGF, and 1% penicillin and 0.1% streptomycin. For transfection, FuGene 6 (Roche Diagnostics, Indianapolis, IN, USA) was used following the manufacturer's instructions. After 48 h transfection, cells were fed with complete medium containing 50 mg/ml hygromycin B (Invitrogen, Carlsbad, CA, USA) and resistant clones were selected for 3 weeks. Final resulting colonies were picked and expanded for further analysis and maintained in 1 mg/ml hygromycin B.
Northern analysis
For Northern analysis, equal amounts of total RNA from ES clones were isolated by using the RNeasy kit (Qiagen, Valencia, CA, USA) and were separated on a 1% formaldep12 CDK2-AP1 knockout induces resistance to cisplatin Y Kim et al hyde agarose gel (2.2 M formaldehyde) in formaldehyde running buffer (40 mM MOPS, pH 7.0, 10 mM sodium acetate, 1 mM EDTA). After electrophoresis, RNA was blotted onto a Nytran membrane (Schleicher and Schuell, Keene, NH, USA) overnight with 20X SSC (3 M NaCl, 300 mM sodium citrate, pH 7.0). The blot was briefly rinsed with 2X SSC and UV crosslinked. Northern hybridization with murine p12 CDK2-AP1 cDNA probe was carried out as described earlier (Kim et al., 2001) .
Western analysis
For Western analysis, cell lysates were isolated and homogenized in 10 volumes of RIPA buffer (10 mM Tris-HCl, pH 7.5; 150 mM NaCl; 5 mM EDTA; 0.5% SDS; 1.0% NP40; 1.0% sodium deoxycholate, containing protease inhibitors). Total cellular protein was prepared and subjected to immunoblot analysis as described previously (Kim et al., 2001) .
Cell proliferation assay and FACS analysis
For cisplatin treatment, the cells were seeded on a 96-well plate (5000 cells/well) and grown overnight. The next day, the cells were fed with fresh medium containing different concentrations of cisplatin (0, 5, 20, and 100 mM). The cells were fed with fresh medium every day and the proliferation of the cells was measured by using the CCK-8 assay reagent (Alexis Biochemical Corp., San Diego, CA, USA) for 5 days following the manufacturer's instructions. CCK-8 assay reagent of 10% of the cell culture medium was added to each well and mixed gently. After 1 h incubation at 371C, 1% SDS of 1/10 volume of the culture medium was added and the absorbance at 450 nm was measured. All the assays were carried out in quadruplicate and the growth rate was presented as fold-increase over the day 1 value. For negative control treatment, the medium was mixed with DMSO only. The effect of cisplatin on cellular proliferation was presented as a ratio to the negative control treatment. For cell cycle profiling by FACS analysis, an equal number of cells were plated on a 100 mm dish and grown until 70% confluency. The cells were harvested by trypsinization and washed twice with PBS. After resuspending in 500 ml of ice-cold PBS, the cells were fixed by mixing with 5 ml of cold 95% ethanol and kept at 41C overnight. The cells were pelleted and washed two times with PBS/1%FBS and finally resuspended in 800 ml of PBS/1%FBS. The cell suspension was mixed with 100 ml of 10X propidium iodide (500 mg/ml in 38 mM sodium citrate, pH 7.0, Sigma, St. Louis, MO) and 100 ml of boiled RNaseA (10 mg/ml in 10 mM Tris-HCl, pH 7.5, Calbiochem, San Diego, CA, USA). After incubating for 30 min at 371C, the cell cycle profile was analysed by FACS analysis.
Host cell reactivation assay on cisplatin-treated DNA For host cell reactivation assay on cisplatin-damaged reporter DNA, pGL3-Luc (Promega, Madison, WI, USA) harboring firefly luciferase was used. Plasmid DNA was treated with different concentrations of cisplatin (0, 1, 5, and 10 mg/ml) for 1 h at 371C and ethanol-precipitated. The DNA pellet was washed three times with 70% ethanol, air-dried, and finally resuspended in TE buffer. Murine ES clones (2 Â 10 4 ) were seeded on a 96-well plate and transiently cotransfected with 100 ng of damaged pGL3-Luc and 50 ng of PRL-CMV (Promega, Madison, WI, USA) harboring Renilla luciferase gene for normalization by using Lipofectamine 2000 reagent (Invitrogen, Carlsbad, CA, USA) following the manufacturer's protocol. After 5 h transfection, the cells were fed with fresh complete medium and further incubated for 24 h before the activity assay. For reporter activity assay, the cells were washed twice with PBS and lysed in 30 ml of passive lysis buffer. Reporter activity was measured by using Dual Luciferase Reporter (DLR) assay kit according to the manufacturer's instructions (Promega, Madison, WI, USA).
In vitro CDK2 kinase assay
Total cell lysate was prepared with 1X lysis buffer (20 mM TrisHCl, pH 7.5, 150 mM NaCl, 1 mM Na 2 EDTA, 1 mM EGTA, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM Na 3 VO 4 , 1 mM NaF, 1 mg/ml leupeptin, 2.5 mg/ml aprotinin, and 1 mM PMSF). In vitro CDK2 kinase assay was performed as described previously (Hu et al., 2004) . Briefly, 1 mg of total cell lysate was incubated with 2 mg of anti-CDK2 antibody (Clone 55, BD Biosciences Pharmingen, San Diego, CA, USA) overnight at 41C. After incubating with 40 ml of protein A/G agarose (Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA) for 2 h at 41C, the beads were washed twice with 1X cell lysis buffer and then twice with 1X kinase buffer (25 mM Tris-HCl, pH 7.5, 1 mM dithiothreitol (DTT), and 10 mM MgCl 2 ). The final pellet was resuspended in 15 ml of 2X kinase buffer and kinase activity assay was carried out by adding 1 mg of Rb-C substrate (Cell Signaling Technology, Beverly, MA, USA), 1 ml of [g-32 P]ATP, and 50 mM ATP. After 30 min incubation at 301C, the reaction was stopped by adding 10 ml of 4X SDS-PAGE sample buffer and boiled for 5 min before loading onto a 10% SDS-PAGE gel. The gel was stained with Coomassie blue and dried before autoradiography.
